Summit Therapeutics SMMT CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's capex?
- Summit Therapeutics (SMMT) reported capex of $245K in Q1 2026.
- How has Summit Therapeutics's capex changed year-over-year?
- Summit Therapeutics's capex decreased by 41.9% year-over-year, from $422K to $245K.
- What is the long-term trend for Summit Therapeutics's capex?
- Over 3 years (2021 to 2025), Summit Therapeutics's capex has grown at a 28.5% compound annual growth rate (CAGR), from $310K to $657K.
- What does capex mean?
- Cash spent on physical assets like buildings, machinery, or equipment.
- How do you interpret capex?
- Higher spending indicates investment in future capacity, while lower spending may indicate a focus on asset-light operations or cost containment.
- How does capex compare across companies?
- Standard metric across all industries; biopharma companies typically have lower CapEx compared to manufacturing firms.